Zentalis Pharmaceuticals (ZNTL) Cash from Operations (2019 - 2026)

Zentalis Pharmaceuticals' Cash from Operations history runs 8 years deep, the most recent figure standing at 32956000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 0.98% year-over-year to 32956000.0 in Q1 2026; TTM through Mar 2026 was 125567000.0, a 17.13% increase from a year earlier, with the FY2025 full-year figure at 125247000.0, up 26.7% from the prior year.
• Cash from Operations slipped to 32956000.0 in Q1 2026 per ZNTL's latest filing, from 30940000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 26963000.0 in Q3 2025 and bottomed at 79275000.0 in Q2 2023.
• The 5-year median for Cash from Operations is 38665000.0 (2023), against an average of 41213882.35.
• Across the five-year window, Cash from Operations slumped 84.24% in 2023 and surged 55.67% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 37329000.0 in 2022, then fell by 8.76% to 40599000.0 in 2023, then climbed by 2.21% to 39702000.0 in 2024, then gained by 22.07% to 30940000.0 in 2025, then decreased by 6.52% to 32956000.0 in 2026.
• Per Business Quant, the three latest ZNTL Cash from Operations figures stand at 32956000.0 (Q1 2026), 30940000.0 (Q4 2025), and 26963000.0 (Q3 2025).